GlassScriptPhysician profile
Uriel S Sandkovsky
NPI 1104060904
$320,005.41
in general payments reported to CMS, 2019-2025
37 companies · $22K in 2025
The $22K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $13K · 2021: $22K · 2022: $42K · 2023: $95K · 2024: $109K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $36K · Consulting Fee: $27K · Travel and Lodging: $15K · Food and Beverage: $11K · Honoraria: $413 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,075.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,650.00 |
| Consulting Fee | $26,830.50 |
| Travel and Lodging | $15,249.57 |
| Food and Beverage | $10,991.07 |
| Honoraria | $413.13 |
| Education | $108.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $86,712.60 | 2021-2025 | Fetroja |
| Pfizer INC. | $67,346.34 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $52,568.23 | 2023-2025 | Vowst |
| Paratek Pharmaceuticals, INC. | $51,559.33 | 2019-2025 | Nuzyra |
| Viiv Healthcare Company | $45,915.94 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Tetraphase Pharmaceuticals, INC. | $4,587.07 | 2019-2020 | |
| Pfizer International LLC | $3,500.00 | 2024 | |
| Insmed, INC. | $1,038.43 | 2019-2025 | Arikayce |
| Gilead Sciences, INC. | $950.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $886.51 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Astellas Pharma US INC | $718.69 | 2019-2025 | Cresemba |
| Emd Serono, INC. | $526.80 | 2019-2024 | Serostim |
| Napo Pharmaceuticals INC | $445.21 | 2019-2024 | Mytesi |
| Abbvie INC. | $442.95 | 2021-2025 | Dalvance, Teflaro |
| Novocure INC. | $413.13 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $315.09 | 2019-2022 | |
| Janssen Biotech, INC. | $304.39 | 2019-2023 | Symtuza |
| Ferring Pharmaceuticals INC. | $295.26 | 2022-2025 | Rebyota |
| Saol Therapeutics INC. | $290.00 | 2019 | |
| La Jolla Pharmaceutical Company | $191.81 | 2020-2024 | Xerava |
| Takeda Pharmaceuticals U.S.A., INC. | $172.57 | 2022-2025 | Livtencity |
| Mayne Pharma Commercial LLC | $160.35 | 2019-2021 | |
| Theratechnologies INC. | $155.97 | 2019-2024 | Egrifta, Trogarzo |
| Octapharma USA, INC. | $104.40 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Melinta Therapeutics, LLC | $98.90 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Amgen INC. | $95.68 | 2019-2024 | Actimmune |
| Hospira, INC. | $69.47 | 2024-2025 | |
| Vbi Vaccine (Delaware) INC. | $29.07 | 2022 | |
| Kci USA, INC. | $25.90 | 2020 | |
| Amarin Pharma, INC. | $22.59 | 2021 | |
| Grifols USA, LLC | $20.84 | 2022 | |
| Genentech USA, INC. | $19.03 | 2019 | |
| Nabriva Therapeutics, Plc | $11.37 | 2021 | |
| Dynavax Technologies Corporation | $11.09 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uriel Sandkovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.